Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Obesity | Research

Association of novel and conventional obesity indices with colorectal cancer risk in older Chinese: a 14-year follow-up of the Guangzhou Biobank Cohort Study

Authors: Shu Yi Wang, Wei Sen Zhang, Chao Qiang Jiang, Ya Li Jin, Tong Zhu, Feng Zhu, Lin Xu

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Visceral adiposity index (VAI) and a body shape index (ABSI) were newly developed indices for visceral fat mass. Whether they are superior to conventional obesity indices in predicting colorectal cancer (CRC) remains unclear. We examined the associations of VAI and ABSI with CRC risk, and investigated their performance in discriminating CRC risk compared with conventional obesity indices in the Guangzhou Biobank Cohort Study.

Methods

A total of 28,359 participants aged 50 + years without cancer history at baseline (2003-8) were included. CRC were identified from the Guangzhou Cancer Registry. Cox proportional hazards regression was used to assess the association of obesity indices with the CRC risk. Discriminative abilities of obesity indices were assessed using Harrell’s C-statistic.

Results

During an average follow-up of 13.9 (standard deviation = 3.6) years, 630 incident CRC cases were recorded. After adjusting for potential confounders, the hazard ratio (95% confidence interval) of incident CRC for per standard deviation increment in VAI, ABSI, body mass index (BMI), waist circumference (WC), waist-to-hip ratio (WHR) and waist-to-height ratio (WHtR) was 1.04 (0.96, 1.12), 1.13 (1.04, 1.22), 1.08 (1.00, 1.17), 1.15 (1.06, 1.24), 1.16 (1.08, 1.25)and 1.13 (1.04, 1.22), respectively. Similar results for colon cancer were found. However, the associations of obesity indices with risk of rectal cancer were non-significant. All obesity indices showed similar discriminative abilities (C-statistics from 0.640 to 0.645), with WHR showing the highest whilst VAI and BMI the lowest.

Conclusions

ABSI, but not VAI, was positively associated with a higher risk of CRC. However, ABSI was not superior to the conventional abdominal obesity indices in predicting CRC.
Appendix
Available only for authorised users
Literature
1.
Sung H, Ferlay J, Siegel RL. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. 2021. 71(3): p. 209–249.
2.
Collaborators GCC. Global, regional, and national burden of colorectal cancer and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019.Lancet Gastroenterol Hepatol, 2022.
3.
4.
Dong Y et al. Abdominal obesity and colorectal cancer risk: systematic review and meta-analysis of prospective studies.Biosci Rep, 2017. 37(6).
5.
Kruschitz R, et al. Detecting body fat-A weighty problem BMI versus subcutaneous fat patterns in athletes and non-athletes. PLoS ONE. 2013;8(8):e72002.PubMedPubMedCentralCrossRef
6.
Shuster A, et al. The clinical importance of visceral adiposity: a critical review of methods for visceral adipose tissue analysis. Br J Radiol. 2012;85(1009):1–10.PubMedPubMedCentralCrossRef
7.
Keum N, et al. Visceral adiposity and colorectal adenomas: dose-response meta-analysis of observational studies. Ann Oncol. 2015;26(6):1101–9.PubMedCrossRef
8.
Amato MC, et al. Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care. 2010;33(4):920–2.PubMedPubMedCentralCrossRef
9.
10.
11.
Thomas DM, et al. Relationships between body roundness with body fat and visceral adipose tissue emerging from a new geometrical model. Obes (Silver Spring). 2013;21(11):2264–71.CrossRef
12.
Consalvo V, et al. ABSI (a body shape index) and ARI (Anthropometric Risk Indicator) in bariatric surgery. First application on a bariatric cohort and possible clinical use. Obes Surg. 2018;28(7):1966–73.PubMedCrossRef
13.
Guerrero-Romero F, Rodríguez-Morán M. Abdominal volume index. An anthropometry-based index for estimation of obesity is strongly related to impaired glucose tolerance and type 2 diabetes mellitus. Arch Med Res. 2003;34(5):428–32.PubMedCrossRef
14.
15.
Ji M, Zhang S, An R. Effectiveness of a body shape index (ABSI) in predicting chronic diseases and mortality: a systematic review and meta-analysis. Obes Rev. 2018;19(5):737–59.PubMedCrossRef
16.
Leite NN, et al. Visceral adiposity index is positively associated with blood pressure: a systematic review. Obes Res Clin Pract. 2021;15(6):546–56.PubMedCrossRef
17.
Wang D, et al. Association between visceral adiposity index and risk of prediabetes: a meta-analysis of observational studies. J Diabetes Investig. 2022;13(3):543–51.PubMedCrossRef
18.
Anoop S et al. A Body shape index significantly predicts MRI-defined abdominal adipose tissue depots in non-obese Asian Indians with type 2 diabetes mellitus. 2020. 8(1).
19.
Okamura T, Hashimoto Y, Hamaguchi M. Visceral Adiposity Index is a predictor of incident colorectal cancer: a population-based longitudinal study. 2020. 7(1).
20.
Christakoudi S, Tsilidis KK. A Body Shape Index (ABSI), hip index, and risk of cancer in the UK Biobank cohort. 2021. 10(16): p.5614–5628.
21.
Parra-Soto S, Malcomson FC. Associations of A Body Shape Index (ABSI) with Cancer Incidence, All-Cause, and at 23 Sites-Findings from the UK Biobank Prospective Cohort Study. 2022. 31(2): p.315–324.
22.
Kabat GC, et al. Risk of breast, endometrial, colorectal, and renal cancers in postmenopausal women in association with a body shape index and other anthropometric measures. Cancer Causes Control. 2015;26(2):219–29.PubMedCrossRef
23.
Samaras K, et al. Subcutaneous and visceral adipose tissue gene expression of serum adipokines that predict type 2 diabetes. Obes (Silver Spring). 2010;18(5):884–9.CrossRef
24.
Bruun JM, et al. Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT): implication of macrophages resident in the AT. J Clin Endocrinol Metab. 2005;90(4):2282–9.PubMedCrossRef
25.
Meira LB, et al. DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. J Clin Invest. 2008;118(7):2516–25.PubMedPubMedCentral
26.
Wensveen FM et al. NK cells link obesity-induced adipose stress to inflammation and insulin resistance. 2015. 16(4): p.376–85.
27.
Tran TT, et al. Hyperinsulinemia, but not other factors associated with insulin resistance, acutely enhances colorectal epithelial proliferation in vivo. Endocrinology. 2006;147(4):1830–7.PubMedCrossRef
28.
Wu X, et al. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest. 1995;95(4):1897–905.PubMedPubMedCentralCrossRef
29.
Harding JL, et al. Comparison of anthropometric measures as predictors of cancer incidence: a pooled collaborative analysis of 11 Australian cohorts. Int J Cancer. 2015;137(7):1699–708.PubMedCrossRef
30.
Andreasson A et al. The prediction of colorectal cancer using anthropometric measures: A Swedish population-based cohort study with 22 years of follow-up. 2019. 7(9): p.1250–1260.
31.
Jiang C, et al. Cohort profile: the Guangzhou Biobank Cohort Study, a Guangzhou-Hong Kong-Birmingham collaboration. Int J Epidemiol. 2006;35(4):844–52.PubMedCrossRef
32.
Consultation WE. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157–63.CrossRef
33.
Alberti, K.G., et al., Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation, 2009. 120(16):1640-5.PubMedCrossRef
34.
Huxley R, et al. Ethnic comparisons of the cross-sectional relationships between measures of body size with diabetes and hypertension. Obes Rev. 2008;9(Suppl 1):53–61.PubMedCrossRef
35.
Browning LM, Hsieh SD, Ashwell M. A systematic review of waist-to-height ratio as a screening tool for the prediction of cardiovascular disease and diabetes: 0·5 could be a suitable global boundary value. Nutr Res Rev. 2010;23(2):247–69.PubMedCrossRef
36.
Sanford NN, et al. Obesity and younger versus older onset colorectal cancer in the United States, 1998–2017. J Gastrointest Oncol. 2020;11(1):121–6.PubMedPubMedCentralCrossRef
37.
Kim H, Giovannucci EL. Sex differences in the association of obesity and colorectal cancer risk. Cancer Causes Control. 2017;28(1):1–4.PubMedCrossRef
38.
39.
40.
Botteri E, et al. Smoking and colorectal Cancer risk, overall and by Molecular Subtypes: a Meta-analysis. Am J Gastroenterol. 2020;115(12):1940–9.PubMedCrossRef
41.
Sayon-Orea C, Martinez-Gonzalez MA, Bes-Rastrollo M. Alcohol consumption and body weight: a systematic review. Nutr Rev. 2011;69(8):419–31.PubMedCrossRef
42.
McNabb S et al. Meta-analysis of 16 studies of the association of alcohol with colorectal cancer. 2020. 146(3): p.861–873.
43.
Song M, Garrett WS, Chan AT. Nutrients, foods, and colorectal cancer prevention. Gastroenterology. 2015;148(6):1244–60e16.PubMedCrossRef
44.
Manser CN, Bauerfeind P. Impact of socioeconomic status on incidence, mortality, and survival of colorectal cancer patients: a systematic review. Gastrointest Endosc. 2014;80(1):42–60e9.PubMedCrossRef
45.
Deng HB, et al. Reliability and validity of the IPAQ-Chinese: the Guangzhou Biobank Cohort study. Med Sci Sports Exerc. 2008;40(2):303–7.PubMedCrossRef
46.
J., et al., A food frequency questionnaire for use in the Chinese population in Hong Kong: Description and examination of validity.Nutrition Research, 1997. 17(11–12): p.1633–1641.
47.
Ye P et al. Linking Obesity with Colorectal Cancer: Epidemiology and Mechanistic Insights.Cancers (Basel), 2020. 12(6).
48.
49.
Virdee PS et al. The Full Blood Count Blood Test for Colorectal Cancer Detection: A Systematic Review, Meta-Analysis, and Critical Appraisal.Cancers (Basel), 2020. 12(9).
50.
51.
52.
53.
54.
Pischon T, et al. Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst. 2006;98(13):920–31.PubMedCrossRef
55.
Freisling H, et al. Comparison of general obesity and measures of body fat distribution in older adults in relation to cancer risk: meta-analysis of individual participant data of seven prospective cohorts in Europe. Br J Cancer. 2017;116(11):1486–97.PubMedPubMedCentralCrossRef
56.
Lear SA, et al. The use of BMI and waist circumference as surrogates of body fat differs by ethnicity. Obes (Silver Spring). 2007;15(11):2817–24.CrossRef
57.
Lim U, et al. Asian women have greater abdominal and visceral adiposity than Caucasian women with similar body mass index. Nutr Diabetes. 2011;1(5):e6.PubMedPubMedCentralCrossRef
58.
Schoen RE, et al. Incidence and mortality of colorectal cancer in individuals with a family history of colorectal cancer. Gastroenterology. 2015;149(6):1438–1445e1.PubMedCrossRef
Metadata
Title
Association of novel and conventional obesity indices with colorectal cancer risk in older Chinese: a 14-year follow-up of the Guangzhou Biobank Cohort Study
Authors
Shu Yi Wang
Wei Sen Zhang
Chao Qiang Jiang
Ya Li Jin
Tong Zhu
Feng Zhu
Lin Xu
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-10762-0

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

Regulation of HHLA2 expression in kidney cancer and myeloid cells

Research

Prognostic value of pre-therapeutic nutritional risk factors in elderly patients with locally advanced esophageal squamous cell carcinoma receiving definitive chemoradiotherapy or radiotherapy

Research

A neoadjuvant therapy compatible prognostic staging for resected pancreatic ductal adenocarcinoma

Research

RTEL1 gene polymorphisms and neuroblastoma risk in Chinese children

Research

Genome instability-related LINC02577, LINC01133 and AC107464.2 are lncRNA prognostic markers correlated with immune microenvironment in pancreatic adenocarcinoma

Research

Circ_0021350 plays an oncogene role by regulating miR-1207-3p/PIK3R3 in glioblastoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits